Current and future therapeutic approaches for osteosarcoma

Douglas J. Harrison, David S. Geller, Jonathan D. Gill, Valerae O. Lewis, Richard Gorlick

Research output: Contribution to journalReview article

105 Scopus citations

Abstract

INTRODUCTION: Current treatment of osteosarcoma includes surgical resection of all gross disease in conjunction with systemic chemotherapy to control micro-metastatic disease. This yields a 5-year event free survival (EFS) of approximately 70% for patients with localized osteosarcoma while patients with metastatic or recurrent disease fare poorly with overall survival rates of less than 20%. Areas covered: This review outlines the current and future approach towards the treatment of osteosarcoma. A literature search was performed utilizing PubMed. Several recent clinical trials are reviewed in detail, as is innovative research evaluating novel agents and surgical techniques which hold promise. Expert commentary: The outcome for patients with osteosarcoma has not changed in several decades. This plateau in survival rates highlights the need for a novel approach towards research. There remains a great deal of interest in utilizing the very high risk population of recurrent osteosarcoma patients to rapidly and sequentially evaluate novel agents to determine if any of these agents hold promise. Several phase II studies are ongoing or in development that offer hope based on intriguing preclinical data. Furthermore, initiatives in obtaining specimens to further explore the genetic and immunological profile behind osteosarcoma will be essential towards identifying novel pathways and targets to exploit.

Original languageEnglish (US)
Pages (from-to)39-50
Number of pages12
JournalExpert Review of Anticancer Therapy
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2018

    Fingerprint

Keywords

  • adjuvant chemotherapy
  • and cisplatin (MAP)
  • doxorubicin
  • limb-salvage
  • methotrexate
  • muramyl tripeptide phosphatidylethanolamine (MTP-PE)
  • neoadjuvant chemotherapy
  • Osteosarcoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this